Clinical trials: HBP
Hypertension
A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension
The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.
- Trial name
- NCT00522925
- Testing
- PS433540
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Ligand Pharmaceuticals
Preeclampsia, Hypertension
Study of Positive Airway Pressure in Preeclampsia to Reduce Blood Pressure
The purpose of this study is to identify whether sleep-disordered breathing - as measured by overnight polysomnography - is associated with pre-eclampsia and to determine whether use of positive airway pressure can improve…
- Trial name
- NCT01029691
- Testing
- Positive Airway Pressure
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Michigan
Vitamin D Deficiency, Pre-Eclampsia
Effect of Vitamin D3 Supplementation in Pregnancy on Risk of Pre-eclampsia
Vitamin D deficient pregnant ladies were selected and randomized into 2 groups for routine daily dose of multivitamin (400IU vitamin D3) versus maximum safest treatment daily dose (4000IU vitamin D3).
- Trial name
- NCT03101150
- Testing
- 400 IU Vitamin D3, 4000 IU Vitamin D3
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- King Fahad Medical City
Hypertension
Conditioned Pharmacotherapeutic Effects in Hypertension
The proposed research is designed to determine if the application of classical conditioning operations could influence the clinical effects of a regimen of antihypertensive drug therapy.
- Trial name
- NCT02056626
- Testing
- carvedilol
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Rochester
Hypertension
Reducing Clinical Inertia in Hypertension Treatment: A Pragmatic Trial
The goal of this project is to use health information technology and team-based care in novel ways to support the establishment of a Patient-Centered Medical Home model of care aimed at improving the diagnosis and management of…
- Trial name
- NCT01145391
- Testing
- Active Outreach to Patients and Providers
- Where
- United States
- Volunteers
- 591 people
- Sponsor
- University of Colorado, Denver
Primary Open-angle Glaucoma
PRESERFLO® MicroShunt Extension Study
This prospective, concurrent controlled, open-label, multicenter study is designed to collect additional safety data through 5 years of follow-up for subjects randomized to either the treatment arm (PRESERFLO® MicroShunt with…
- Trial name
- NCT04333433
- Testing
- PRESERFLO® MicroShunt, Trabeculectomy
- Where
- 23 sites in United States, France and 3 more
- Volunteers
- 279 people
- Sponsor
- InnFocus Inc.
Hypertension
Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons
The overall hypothesis of this trial is that screening for chronic kidney disease, followed by education or treatment program will improve blood pressure control among hypertensive non-diabetic persons.
- Trial name
- NCT02059408
- Testing
- Screen-Educate, Screen-Educate and Intensify Treatment
- Where
- United States
- Volunteers
- 1,819 people
- Sponsor
- University of California, San Francisco
Hypertension
Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension
This study will evaluate the efficacy and safety of valsartan and amlodipine in fixed dose combination in adults with moderate, inadequately controlled hypertension.
- Trial name
- NCT00523744
- Testing
- Amlodipine, Olmesartan medoxomil, Amlodipine+valsartan
- Where
- 2 sites in Germany
- Volunteers
- 257 people
- Sponsor
- Novartis
Pulmonary Arterial Hypertension, Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease…
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Scleroderma Spectrum of Diseases, Connective Tissue Disease
- Trial name
- ATPAHSS (NCT01042158)
- Testing
- tadalafil and ambrisentan upfront combination therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the…
- Trial name
- A DUE (NCT03904693)
- Testing
- FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 187 people
- Sponsor
- Actelion
Hypertension
The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial
This is a randomized, double-blind, double-dummy, parallel group trial employing 15 cells of a 4x4 factorial design (no placebo)to compare the hypertensive effects in patients with Stage 1 and Stage 2 hypertension of carvedilol…
- Trial name
- NCT00347360
- Testing
- lisinopril, carvedilol controlled release formulation
- Where
- 151 sites in United States
- Volunteers
- 654 people
- Sponsor
- GlaxoSmithKline
Glaucoma
Lucentis Versus Mitomycin C During Glaucoma Surgery
Does a new add on (or adjunctive) therapy used in glaucoma surgery improve the success of trabeculectomy? Ranibizumab may offer benefit similar to mitomycin C in preventing epi-scleral fibrosis while avoiding the well known…
- Trial name
- NCT00626782
- Testing
- Ranibizumab, Mitomycin (MMC)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wills Eye
Systemic Sclerosis, Pulmonary; Hypertension
Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
A double-blinded, placebo-controlled study of Dimethyl fumarate (DMF) in 34 Systemic Sclerosis-Pulmonary Hypertension (SSc-PAH) patients.
- Trial name
- NCT02981082
- Testing
- Dimethyl Fumarate (DMF)
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Robert Lafyatis
Essential Hypertension
Perindopril Amlodipine for the Treatment of Hypertension
The purpose of the study is to evaluate the safety and efficacy of a fixed-dose combination drug compared to two other drugs (monotherapies) in controlling hypertension.
- Trial name
- PATH (NCT01556997)
- Testing
- XOMA 985, Amlodipine Besylate, Perindopril Erbumine
- Where
- 48 sites in United States
- Volunteers
- 837 people
- Sponsor
- Symplmed Pharmaceuticals LLC
Pulmonary Arterial Hypertension
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
To assess the efficacy and safety of sildenafil when added to patients with PAH who are taking bosentan as all or part of their background therapy.
- Trial name
- NCT00323297
- Testing
- Bosentan, Sildenafil Citrate
- Where
- 30 sites in United States, Australia and 8 more
- Volunteers
- 105 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
Sitaxsentan has a low drug-drug interaction potential and it did not have a clinically relevant effect on pharmacokinetics of sildenafil (a CYP3A sensitive substrate and PDE5 inhibitor).
- Trial name
- NCT01244620
- Testing
- sitaxentan, tadalafil, sitaxsentan
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Glaucoma, Open-Angle, Hypertension, Ocular
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 ophthalmic solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT03657797
- Testing
- NCX 470, Latanoprost 0.005%
- Where
- United States
- Volunteers
- 656 people
- Sponsor
- Nicox Ophthalmics, Inc.
Hypertension
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension
This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.
- Trial name
- NCT00631917
- Testing
- Aliskiren, Ramipril
- Where
- 7 sites in United States, Argentina and 5 more
- Volunteers
- 774 people
- Sponsor
- Novartis
Hypertension
52-104 Week Off-therapy Second Extension to Study CSPP100A2365
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1
- Trial name
- NCT01420068
- Testing
- SPP100
- Where
- 25 sites in United States, Guatemala and 5 more
- Volunteers
- 106 people
- Sponsor
- LXO Group
Glaucoma
Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma
The primary objective of the study is to assess the safety and tolerability of a 180μg/ml TID dose regimen of recombinant human nerve growth factor (rhNGF) eye drop solution administered over 8 weeks versus a vehicle control in…
- Trial name
- NGF-Glaucoma (NCT02855450)
- Testing
- rhNGF, Vehicle
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Dompé Farmaceutici S.p.A
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.